- Companies
- DNA X
DNA X Valuation Multiples
DNA X is valued at $3M as of November 2026. In the last fiscal year, DNA X EBITDA was ($2M).
DNA X Overview
About DNA X
DNA X, Inc. was formerly Sonim Technologies, a maker of rugged mobile phones, and changed its name in 2026. It now operates the DNA X digital asset trading platform that it acquired in December 2025. Its shares trade on Nasdaq under the ticker SONM.
Founded
1999
HQ
Employees
160
Website
Financials (Last FY)
EV
$4M
Valuation Multiples
Start free trialDNA X Financials
DNA X reported last fiscal year revenue of - and negative EBITDA of ($2M).
In the same fiscal year, DNA X generated - in gross profit, ($2M) in EBITDA losses, and had net loss of ($21M).
DNA X P&L
In the most recent fiscal year, DNA X reported revenue of - and EBITDA of ($2M).
DNA X is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.
Financial data powered by Morningstar, Inc.
DNA X Stock Performance
DNA X has current market cap of $3M, and enterprise value of $4M.
Market Cap Evolution
DNA X's stock price is $1.68.
DNA X share price decreased by 38.3% in the last 30 days.
DNA X has an EPS (earnings per share) of $-13.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $3M | -19.8% | -38.3% | -54.0% | - | $-13.88 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDNA X Valuation Multiples
DNA X trades at (1.8x) EV/EBITDA.
DNA X Financial Valuation Multiples
As of November 19, 2026, DNA X has market cap of $3M and EV of $4M.
DNA X has a P/E ratio of (0.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DNA X Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


DNA X Margins & Growth Rates
DNA X Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
DNA X Operational KPIs
DNA X's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
DNA X Competitors
DNA X competitors include Ordissimo, Weaccess Group, Cyfrowe Centrum Serwisowe, Arzneiwerk VIDA, Immersion SA, Verbicom, Boxlight, AGM Group Holdings, Pentanet and Exalt.
Most DNA X public comparables operate across Computer Hardware, Telecom Service Providers, Networking Hardware and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4M | $245K | 1.2x | - | 19.2x | - | |||
| $1M | $271K | 2.5x | - | 9.9x | - | |||
| $28M | $169K | 0.1x | - | 10.0x | - | |||
| $75K | ($400K) | 25.1x | - | (4.7x) | - | |||
| $6M | ($797K) | 0.4x | - | (3.0x) | - | |||
| $11M | $24K | 0.5x | - | 224.6x | - | |||
| $109M | ($4M) | 0.3x | 0.3x | (8.6x) | - | |||
| $31M | $4M | 0.1x | - | 0.9x | - | |||
This data is available for Pro users. Sign up to see all DNA X competitors and their valuation data. Start Free Trial | ||||||||
DNA X VC Funding History
Before going public, DNA X raised $35M in total equity funding, across 2 rounds.
DNA X Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DNA X
| When was DNA X founded? | DNA X was founded in 1999. |
| Where is DNA X headquartered? | DNA X is headquartered in United States. |
| How many employees does DNA X have? | As of today, DNA X has over 160 employees. |
| Is DNA X publicly listed? | Yes, DNA X is a public company listed on Nasdaq. |
| What is the stock symbol of DNA X? | DNA X trades under SONM ticker. |
| When did DNA X go public? | DNA X went public in 2019. |
| Who are competitors of DNA X? | DNA X main competitors include Ordissimo, Weaccess Group, Cyfrowe Centrum Serwisowe, Arzneiwerk VIDA, Immersion SA, Verbicom, Boxlight, AGM Group Holdings, Pentanet, Exalt. |
| What is the current market cap of DNA X? | DNA X's current market cap is $3M. |
| Is DNA X profitable? | No, DNA X is not profitable. |
| What is the current net income of DNA X? | DNA X's last 12 months net income is ($21M). |
| How many companies DNA X has acquired to date? | DNA X hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies DNA X has invested to date? | DNA X hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to DNA X
Lists including DNA X
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




